If there’s one thing that the biotech hub crowd in Boston/Cambridge is particularly good at, it’s raising money. After creating one of the biggest concentrations of drug development operations in the world in and around greater Boston, the money-raising side of the business is now humming like a well-oiled machine.
In a new industry hub snapshot out this morning, the Massachusetts Biotechnology Council — better known as MassBio — happily boasted about the fact that 48% of all US biotech IPOs occurred inside the state in 2017. In 2016, it was 30%.
The 15 newly public biotechs from Massachusetts that jumped into Nasdaq this year have already pushed past the full-year mark for all the IPOs completed in 2017. VCs, meanwhile, invested a record $3.1 billion in Massachusetts companies last year, with a $2.7 billion flood in the first 6 months of this year which will soon sweep away the record book.
Underscoring a global trend, rounds are getting bigger fast, with the average deal size growing from $34 million in 2017 to $51 million in the first half of this year.
The full report also underscores how fast things continue to change at the top. Pulling a list of the top industry employers from the Boston Business Journal, this new report highlights Sanofi as the biggest player by staff size in the state — which is what you would expect after the Genzyme acquisition. But two other top-10 players, Takeda and Shire, are in the process of merging.
That could create a new number 1 in the the employment arena, unless Takeda ends up axing its way back to the number 2 slot.
What’s the money and the jobs focused on?
Not surprisingly, cancer grabs the lion’s share of the attention. Here’s their pie chart on the pipeline and the would-be products you’ll find inside:
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,100+ biopharma pros who read Endpoints News by email every day.Free Subscription